Optimeos Life Sciences Receives Investment From Hatch BioFund

The company plans to use the funding to expand its operations and continue developing its technology.

Optimeos, based in Princeton, New Jersey, has developed a non-viral nanoparticle drug delivery platform called Coated Inverse Nanocarriers (CINCs). The patented technology was developed over more than 20 years in the laboratory of Princeton University Professor Robert Prud'homme.

Read More:Neurometric Raises $4M in Funding by Mu Ventures

The platform can efficiently deliver a wide range of therapies, including biologics, peptides, RNA, and DNA. It is designed to support tissue targeting, adjustable immune responses, and improved dosing, with encapsulation efficiency of more than 90%.

The technology is being used in the company's lead gene replacement therapy for the rare disease CTLN1, as well as programs in T-cell engineering and targeted lung therapies. Optimeos is also partnering with biopharmaceutical companies to develop new treatments for a range of diseases.

"Optimeos was founded on the conviction that the next great wave of medicine — RNA, DNA, and biologic therapies — will only reach its potential if we can deliver these molecules precisely, efficiently, and durably to the right cells and tissues," said Shahram Hejazi, Ph.D., Co-Founder and CEO of Optimeos. "We are thrilled to have Hatch join us on our mission to address one of the most consequential bottlenecks in modern drug development: how to deliver complex therapeutic molecules safely, precisely, and at scale."

"We are proud to welcome Optimeos to our portfolio," said Lorenzo Pellegrini, Ph.D., Managing Partner of Hatch BioFund. "Optimeos represents exactly the kind of company Hatch was built to support — exceptional science from a world-class academic institution, a seasoned leadership team, and a platform technology with the potential to unlock an entirely new generation of medicines. We look forward to partnering with the Optimeos team as they bring their technology to its full commercial potential."

"It is gratifying to see the technology developed in my laboratory over twenty years attracting the investment and partnerships necessary to make a real difference in patients' lives," said Robert Prud'homme, Ph.D., Co-Founder and Professor Emeritus of Chemical and Biological Engineering at Princeton University. "The CINC platform is transformational - it opens possibilities for RNA, DNA, and biologic medicines that simply were not achievable before. Hatch‘s investment is an important milestone in bringing that promise to fruition."

About Optimeos Life Sciences

Founded by Shahram Hejazi, Optimeos is developing a pipeline of therapies based on its non-viral drug delivery platform. The technology is designed to safely and efficiently deliver complex therapies, including gene therapies and biologics.

Originally developed in Professor Robert Prud'homme's laboratory at Princeton University, the platform addresses key limitations of current lipid nanoparticle delivery systems. Optimeos is advancing lead programs in non-viral gene therapies for in vivo CAR-T and rare metabolic diseases, while also working with industry partners to develop new treatments.

Read More:Arca Raises $48.5M in Series A Funding Led by General Catalyst